Addex Therapeutics Ltd ADXN
NASDAQ
| 03/31/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -87.35% |
| Total Other Revenue | -- | -- | -- | -- | 1,550.98% |
| Total Revenue | -- | -- | -- | -- | -81.84% |
| Cost of Revenue | -- | -- | -- | -- | -35.31% |
| Gross Profit | -- | -- | -- | -- | -407.91% |
| SG&A Expenses | -- | -- | -- | -- | -27.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | -- | -30.04% |
| Operating Income | -- | -- | -- | -- | 3.95% |
| Income Before Tax | -- | -- | -- | -- | -96.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | -- | -96.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 267.42% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -- | 174.52% |
| EBIT | -- | -- | -- | -- | 3.95% |
| EBITDA | -- | -- | -- | -- | 10.71% |
| EPS Basic | -- | -- | -- | -- | 162.83% |
| Normalized Basic EPS | -- | -- | -- | -- | -66.94% |
| EPS Diluted | -- | -- | -- | -- | 161.20% |
| Normalized Diluted EPS | -- | -- | -- | -- | -66.94% |
| Average Basic Shares Outstanding | -- | -- | -- | -- | 17.99% |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | 17.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |